You are here: Home » International » News » Companies
Business Standard

Glenmark gets USFDA nod for Aprepitant capsules; cancer patients to benefit

Aprepitant capsules are used to prevent nausea caused by cancer chemotherapy

Press Trust of India  |  New Delhi 

Glenmark office
Glenmark office

Pharmaceuticals on Monday said its US-based arm has received final approval from the (USFDA) for Aprepitant capsules, used for preventing nausea caused by

Pharmaceuticals Inc, USA, has received final approval by the for USP, 40 mg, 80 mg, and 125 mg, the company said in a regulatory filing.

The tablets are generic versions of Merck Sharp & Dohme Corporation's Emend capsules, it added.

According to IMS health sales data for the 12 months ended August, Emend Capsules, 40 mg, 80 mg, and 125 mg achieved annual sales of around $64.9 million, said.

The company's current portfolio consists of 127 products authorised for distribution in the US marketplace and 60 abbreviated new drug applications (ANDAs) which are pending approval with the USFDA, it added.

Shares of Pharmaceuticals rose by 0.63 per cent to Rs 607 in morning trade on BSE.

First Published: Mon, October 16 2017. 13:13 IST